CMPXCompass Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $1.83 · now $1.83 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, CMPX has typically landed between $1.26 and $2.54 — a range of −31.0% to +39.0% from the issuance price $1.83.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,348 overlapping 1 month windows · 2021-04-052026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($1.83) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where CMPX has typically landed a month from the 2026-09-16 close of $1.83 — the range is history, not a prediction.

$1.26worst · -31.0%$2.54best · +39.0%
  • now $1.83 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $1.82 (-0.6%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $1.57$2.07
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.26$2.54
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,348 windows spanning 2021-04-05 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2026-04-16−72.0%−74.4%+0.0%
2026-04-17−69.8%−72.2%+0.0%
2026-04-15−68.2%−71.5%+11.6%
3 best
2025-01-07+144.8%+0.0%+144.8%
2024-12-19+126.3%+0.0%+126.3%
2025-01-02+122.9%+0.0%+130.0%

1,348 overlapping windows · 2021-04-052026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
40%
+11.9%
n=5
Feb
40%
+5.2%
n=5
Mar
20%
−15.2%
n=5
Apr
20%
−19.2%
n=5
May
50%
+18.0%
n=6
Jun
50%
−0.6%
n=6
Jul
50%
−0.7%
n=6
Aug
67%
+9.1%
n=6
Sep
33%
−7.0%
n=6
Oct
40%
+2.9%
n=5
Nov
60%
+16.2%
n=5
Dec
20%
−0.3%
n=5

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$7$2↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-05-27Schuetz Thomas J.directorPurchase10,000 @ $2.11$21K+0.2% of holding+19.4%+120.8%6,480,825Form 4 · filed same day
2025-04-09ORBIMED ADVISORS LLCdirectorSale3,571,428 @ $1.59$5.7M−100.0% of holding+1.1%+109.5%0Form 4 · filed 2 days after the trade
2025-04-09GORDON CARL LdirectorSale3,571,428 @ $1.59$5.7M−100.0% of holding+1.1%+109.5%0Form 4 · filed 2 days after the trade
2025-04-07Anderman JonathanofficerPurchase20,000 @ $1.54$31K+2000.0% of holding+0.8%+96.5%21,000Form 4 · filed 1 day after the trade
2025-04-07Lerner NeilofficerPurchase20,000 @ $1.42$28K+6.7% of holding+0.8%+96.5%320,000Form 4 · filed 1 day after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

35 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-04-29Anderman JonathanofficerAward / grant25,000196,000Form 4
2026-04-29Lerner NeilofficerAward / grant15,000397,500Form 4
2026-02-08Schuetz Thomas J.directorWithheld for tax36,6876,603,336Form 4
2026-01-09Schuetz Thomas J.directorWithheld for tax46,7776,640,023Form 4
2026-01-02Schuetz Thomas J.directorAward / grant250,0006,686,800Form 4
2026-01-02Anderman JonathanofficerAward / grant150,000171,000Form 4
2026-01-02Shin BarryofficerAward / grant125,000525,000Form 4
2026-01-02Lerner NeilofficerAward / grant62,500382,500Form 4
2026-01-02Schuetz Thomas J.directorAward / grant2,000,0002,000,000Form 4
2026-01-02Sirard CynthiaofficerAward / grant1,000,0001,000,000Form 4
2026-01-02Anderman JonathanofficerAward / grant720,000720,000Form 4
2026-01-02Shin BarryofficerAward / grant670,000670,000Form 4
2026-01-02Boylan James PdirectorAward / grant90,00090,000Form 4
2026-01-02Chiniara EllendirectorAward / grant90,00090,000Form 4
2026-01-02LINDAHL RICHARD SdirectorAward / grant90,00090,000Form 4
2026-01-02Ferneau PhilipdirectorAward / grant90,00090,000Form 4
2026-01-02GORDON CARL LdirectorAward / grant90,00090,000Form 4
2026-01-02GRAY MARY ANNdirectorAward / grant90,00090,000Form 4
2026-01-02Prasad ArjunofficerAward / grant1,000,0001,000,000Form 4
2026-01-02Lerner NeilofficerAward / grant435,000435,000Form 4
2025-11-16Schuetz Thomas J.directorWithheld for tax44,0256,436,800Form 4
2025-02-11Schuetz Thomas J.directorAward / grant1,500,0001,500,000Form 4
2025-02-11Shin BarryofficerAward / grant250,000250,000Form 4
2025-02-11GRAY MARY ANNdirectorAward / grant40,00040,000Form 4
2025-02-11Anderman JonathanofficerAward / grant280,000280,000Form 4
2025-02-11Boylan James PdirectorAward / grant40,00040,000Form 4
2025-02-11Ferneau PhilipdirectorAward / grant40,00040,000Form 4
2025-02-11GORDON CARL LdirectorAward / grant40,00040,000Form 4
2025-02-11LINDAHL RICHARD SdirectorAward / grant40,00040,000Form 4
2025-02-11Lerner NeilofficerAward / grant200,000200,000Form 4
2025-02-11Chiniara EllendirectorAward / grant40,00040,000Form 4
2025-02-08Schuetz Thomas J.directorWithheld for tax41,6876,470,825Form 4
2025-01-09Schuetz Thomas J.directorWithheld for tax58,0546,512,512Form 4
2024-12-09Shin BarryofficerAward / grant400,000400,000Form 4
2024-12-09Shin BarryofficerAward / grant400,000400,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.